Submission Details

RAL-THA-6ca1b233
Molecule(s):
C#Cc1ccc2c(c1)C(C(=O)Nc1nncn1C1CC1)CCO2

RAL-THA-6ca1b233-1

C#Cc1ccc2c(c1)C(C(=O)Nc1nncn1C1CC1)CCO2

3-aminopyridine-like Check Availability on Manifold View
CCc1ccc2c(c1)C(C(=O)Nc1nncn1C1CC1)CCO2

RAL-THA-6ca1b233-2

CCc1ccc2c(c1)C(C(=O)Nc1nncn1C1CC1)CCO2

3-aminopyridine-like Check Availability on Manifold View
O=C(Nc1nncn1C1CC1)C1CCOc2ccc(CO)cc21

RAL-THA-6ca1b233-3

O=C(Nc1nncn1C1CC1)C1CCOc2ccc(CO)cc21

3-aminopyridine-like Check Availability on Manifold View
O=C(Nc1nncn1C1CC1)C1CCOc2ccc(C(F)F)cc21

RAL-THA-6ca1b233-4

O=C(Nc1nncn1C1CC1)C1CCOc2ccc(C(F)F)cc21

3-aminopyridine-like Check Availability on Manifold View
Design Rationale:

Expansion/exploration of JAG-UCB-a3ef7265-20. Additional targets to explore binding in the "P2 pocket". Along with the CN analog proposed by Ed Griffen, these can be obtained via the corresponding Br analog - Sonogashira coupling, etc.

Inspired By:
Discussion:

Contributor: Ralph Robinson, Thames Pharma Partners - Thu, 25 Jun 2020 14:34:45 +0000